Abstract
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, show dramatic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations. However, 25% – 30% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Three mechanisms — second-site point mutation that substitutes methionine for threonine at position 790 (T790M) in EGFR, amplification of MET protooncogene, and overexpression of hepatocyte growth factor (HGF, a ligand of MET) — have been reported to contribute to resistance to EGFR-TKIs. These three factors were detected simultaneously in a population of patients with acquired resistance to EGFR-TKIs. Further investigations to develop optimal therapy based on accurate diagnosis of resistant mechanism are warranted to improve the prognosis of EGFR mutant lung cancer.
Keywords: Acquired resistance, EGFR mutation, gene amplification, lung cancer, tyrosine kinase inhibitor, HGF, gefitinib, erlotinib, intrinsic resistance, T790M mutation, Met amplification, fibroblasts, microenvironment, EGFR-TKI, ErbB3, PI3K, Akt
Current Signal Transduction Therapy
Title: HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer
Volume: 6 Issue: 2
Author(s): Seiji Yano, Wei Wang, Qi Li, Tadaaki Yamada, Shinji Takeuchi, Kunio Matsumoto, Yasuhiko Nishioka and Saburo Sone
Affiliation:
Keywords: Acquired resistance, EGFR mutation, gene amplification, lung cancer, tyrosine kinase inhibitor, HGF, gefitinib, erlotinib, intrinsic resistance, T790M mutation, Met amplification, fibroblasts, microenvironment, EGFR-TKI, ErbB3, PI3K, Akt
Abstract: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, show dramatic effects against non-small cell lung cancer (NSCLC) with EGFR activating mutations. However, 25% – 30% of EGFR mutant lung cancer patients show intrinsic resistance, and the responders almost invariably acquire resistance to EGFR-TKIs within several years. Three mechanisms — second-site point mutation that substitutes methionine for threonine at position 790 (T790M) in EGFR, amplification of MET protooncogene, and overexpression of hepatocyte growth factor (HGF, a ligand of MET) — have been reported to contribute to resistance to EGFR-TKIs. These three factors were detected simultaneously in a population of patients with acquired resistance to EGFR-TKIs. Further investigations to develop optimal therapy based on accurate diagnosis of resistant mechanism are warranted to improve the prognosis of EGFR mutant lung cancer.
Export Options
About this article
Cite this article as:
Yano Seiji, Wang Wei, Li Qi, Yamada Tadaaki, Takeuchi Shinji, Matsumoto Kunio, Nishioka Yasuhiko and Sone Saburo, HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795659928
DOI https://dx.doi.org/10.2174/157436211795659928 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Association of Smoking and Alcohol Drinking with Dementia Risk Among Elderly Men in China
Current Alzheimer Research Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Exploration of Metastasis-related Proteins as Biomarkers and Therapeutic Targets in the Treatment of Head and Neck Cancer
Current Cancer Drug Targets Metabolomics Analysis for Biomarker Discovery: Advances and Challenges
Current Medicinal Chemistry Traditional Fruits of Kerala: Bioactive Compounds and their Curative Potential in Chronic Diseases
Current Nutrition & Food Science Novel Aminopeptidase N Inhibitors with Improved Antitumor Activities
Letters in Drug Design & Discovery Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Cordycepin Suppresses Integrin/FAK Signaling and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Recent Development in [1,4]Benzodiazepines as Potent Anticancer Agents: A Review
Mini-Reviews in Medicinal Chemistry On the Origin of Epidermal Cancers
Current Molecular Medicine γ-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease
Current Topics in Medicinal Chemistry Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Design, Synthesis and Pharmacological Evalution of 1,3,4-Oxadiazole Derivatives as Collapsin Response Mediator Protein 1 (CRMP 1) Inhibitors
Current Drug Discovery Technologies Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment
Current Medicinal Chemistry Antisense Treatment in Human Prostate Cancer and Melanoma
Current Cancer Drug Targets HIV1-Human Protein-Protein Interaction Prediction (HHPPIP) Methodology: An FP-Growth Based Association Rule Mining Approach
Current Bioinformatics